Seven weeks after administration, we performed an oral glucose tolerance test (OGTT, 2 g/kg body weight of a 30% dextrose solution) and found that delivery of AAV8 Ins1-Cre up to a dose of 1 × 1012 VGP did not alter glucose excursions; however, 3 × 1012 VGP caused glucose intolerance (Fig. 1b). This evidence concerns the gene FOXM1 and Glucose intolerance.